瑞舒伐他汀对置入冠状动脉支架患者的近期疗效
|
摘要
目的探讨瑞舒伐他汀对置入冠状动脉支架患者的近期疗效。方法选取2014年9月～2016年8月在青海大学附属医院行冠状动脉介入治疗并置入冠状动脉支架的冠心病患者87例,根据随机数表法分为瑞舒伐他汀组(42例)和阿托伐他汀组(45例)。瑞舒伐他汀组给予瑞舒伐他汀钙片治疗,阿托伐他汀组给予阿托伐他汀钙片治疗,比较两组患者临床疗效及心源性死亡、非致死性心肌梗死、靶血管重建术、支架内血栓形成及出血事件。结果瑞舒伐他汀组总有效率为92.86%,低于阿托伐他汀组的95.56%,差异无统计学意义(P>0.05)。两组心源性死亡、非致死性心肌梗死、靶血管血运重建、支架内血栓形成和出血事件比较,差异无统计学意义(P>0.05)。结论瑞舒伐他汀与阿托伐他汀治疗置入冠状动脉支架患者的疗效相近,具有一定的临床疗效。
Objective To investigate the short-term efficacy of rosuvastatin in patients with coronary stents. Methods From September 2014 to August 2016, 87 patients with coronary artery disease who underwent coronary intervention and were placed in coronary stents at Qinghai University Hospital were enrolled. According to the random number table method, they were divided into rosuvastatin group(42 cases) and atorvastatin group(45 cases). The rosuvastatin group was treated with rosuvastatin calcium tablets, and the atorvastatin group was treated with atorvastatin calcium tablets.The clinical efficacy and cardiac death, nonfatal myocardial infarction, and target revascularization were compared between the two groups,stent thrombosis and bleeding events. Results The total effective rate of rosuvastatin group was 92.86%, which was lower than that of atorvastatin group95.56%,the difference was not statistically significant(P>0.05). There were no significant differences between the two groups in cardiac death, nonfatal myocardial infarction, target vessel revascularization, stent thrombosis and hemorrhagic events(P>0.05). Conclusion The efficacy of rosuvastatin and atorvastatin in the treatment of coronary stents is similar and has a certain clinical effect.
Objective To investigate the short-term efficacy of rosuvastatin in patients with coronary stents. Methods From September 2014 to August 2016, 87 patients with coronary artery disease who underwent coronary intervention and were placed in coronary stents at Qinghai University Hospital were enrolled. According to the random number table method, they were divided into rosuvastatin group(42 cases) and atorvastatin group(45 cases). The rosuvastatin group was treated with rosuvastatin calcium tablets, and the atorvastatin group was treated with atorvastatin calcium tablets.The clinical efficacy and cardiac death, nonfatal myocardial infarction, and target revascularization were compared between the two groups,stent thrombosis and bleeding events. Results The total effective rate of rosuvastatin group was 92.86%, which was lower than that of atorvastatin group95.56%,the difference was not statistically significant(P>0.05). There were no significant differences between the two groups in cardiac death, nonfatal myocardial infarction, target vessel revascularization, stent thrombosis and hemorrhagic events(P>0.05). Conclusion The efficacy of rosuvastatin and atorvastatin in the treatment of coronary stents is similar and has a certain clinical effect.
引文
[1]Ye Z,Lu H,Su Q,et al.Short-term and long-term effects of a loading dose of atorvastatin before percutaneous coronary intervention on major adverse cardiovascular events in patients with acute coronary syndrome:A meta-analysis of 13 randomized controlled trials[J].Eur Heart J,2019,40(1):1-10.
[2]赵川,王翠兰,宋宏界,等.阿托伐他汀经皮冠脉介入治疗急性心肌梗死的疗效观察[J].中国实用医药,2018,13(25):88-89.
[3]中华医学会心血管病学分会介入心脏病学组,中国医师协会心血管内科医师分会血栓防治专业委员会,中华心血管病杂志编辑委员会.中国经皮冠状动脉介入治疗指南(2016)[J].中华心血管病杂志,2016,44(5):382-400.
[4]杨美艳,韩博,田留洋,等.高龄急性冠状动脉综合征患者应用阿托伐他汀与瑞舒伐他汀对氯吡格雷抗血小板活性的影响[J].解放军医学院学报,2015,36(12):1208-1210.
[5]高晗,赵侃,尹雪松,等.瑞舒伐他汀和阿托伐他汀在急性冠脉综合症中对氯吡格雷抗血小板活性的对比研究[J].现代生物医学进展,2014,14(4):697-699.
[6]Sardella G,Lucisano L,Mancone M,et al.Comparison of high reloading ROsuvastatin and Atorvastatin pretreatment in patients undergoing elective PCI to reduce the incidence of MyocArdial periprocedural necrosis[J].Int J Cardiol,2013,168(4):3715-3720.
[7]吴萃荣,王湛.瑞舒伐他汀与阿托伐他汀对急性心肌梗死患者PCI术后左室重构及近期预后影响的比较[J].实用医学杂志,2015,31(3):470-472.
[8]韩宝华,罗晓婷.瑞舒伐他汀对急性冠脉综合征患者支架置入术后再狭窄的影响[J].中国循证心血管医学杂志,2017,9(7):842-847.
[9]叶慧明,彭建军,任利辉,等.阿托伐他汀或瑞舒伐他汀与氯吡格雷合用在非ST段抬高型急性冠状动脉综合征患者支架置入术后的近期疗效比较[J].中国心血管杂志,2012,17(3):185-188.
[10]Leoncini M,Toso A,Maioli M.Statin andclopidogrelpharmacological interaction[J].G Ital Cardiol,2013,14(9):574-584.
[11]盛国太,徐秀秀,葛郁芝.影响氯吡格雷药效及其代谢的相关因素[J].中国新药杂志,2017,26(23):2794-2798.
[2]赵川,王翠兰,宋宏界,等.阿托伐他汀经皮冠脉介入治疗急性心肌梗死的疗效观察[J].中国实用医药,2018,13(25):88-89.
[3]中华医学会心血管病学分会介入心脏病学组,中国医师协会心血管内科医师分会血栓防治专业委员会,中华心血管病杂志编辑委员会.中国经皮冠状动脉介入治疗指南(2016)[J].中华心血管病杂志,2016,44(5):382-400.
[4]杨美艳,韩博,田留洋,等.高龄急性冠状动脉综合征患者应用阿托伐他汀与瑞舒伐他汀对氯吡格雷抗血小板活性的影响[J].解放军医学院学报,2015,36(12):1208-1210.
[5]高晗,赵侃,尹雪松,等.瑞舒伐他汀和阿托伐他汀在急性冠脉综合症中对氯吡格雷抗血小板活性的对比研究[J].现代生物医学进展,2014,14(4):697-699.
[6]Sardella G,Lucisano L,Mancone M,et al.Comparison of high reloading ROsuvastatin and Atorvastatin pretreatment in patients undergoing elective PCI to reduce the incidence of MyocArdial periprocedural necrosis[J].Int J Cardiol,2013,168(4):3715-3720.
[7]吴萃荣,王湛.瑞舒伐他汀与阿托伐他汀对急性心肌梗死患者PCI术后左室重构及近期预后影响的比较[J].实用医学杂志,2015,31(3):470-472.
[8]韩宝华,罗晓婷.瑞舒伐他汀对急性冠脉综合征患者支架置入术后再狭窄的影响[J].中国循证心血管医学杂志,2017,9(7):842-847.
[9]叶慧明,彭建军,任利辉,等.阿托伐他汀或瑞舒伐他汀与氯吡格雷合用在非ST段抬高型急性冠状动脉综合征患者支架置入术后的近期疗效比较[J].中国心血管杂志,2012,17(3):185-188.
[10]Leoncini M,Toso A,Maioli M.Statin andclopidogrelpharmacological interaction[J].G Ital Cardiol,2013,14(9):574-584.
[11]盛国太,徐秀秀,葛郁芝.影响氯吡格雷药效及其代谢的相关因素[J].中国新药杂志,2017,26(23):2794-2798.